TBC1D22B

Across TCGA pan-cancer cohorts, TBC1D22B RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of TBC1D22B’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where TBC1D22B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TBC1D22B is over-expressed in tumor, although a few such as KICH and READ show the opposite, repressed pattern.

LIHC, KICH, and KIRP are the cancer types where TBC1D22B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TBC1D22B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.416	<.001	9	view →
KICH	Female	II,III,IV	−1.165	<.001	8	view →
KIRP	All	All	+0.448	<.001	7	view →
LUAD	All	All	+0.253	<.001	6	view →
CHOL	Male	All	+2.643	<.001	5	view →
KIRC	Female	All	+0.445	<.001	5	view →
LUSC	Male	All	+0.341	<.001	5	view →
BRCA	All	All	+0.179	.009	4	view →
STAD	All	II,III,IV	+0.513	.009	3	view →
READ	All	All	−0.362	.020	2	view →
COAD	Female	All	−0.247	.011	2	view →
PRAD	All	All	+0.214	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

TBC1D22B–LIHC

Open the LIHC breakdown →